Which agents should we use to treat and prevent influenza in 2006-2007?
Mossad
Sherif B
SB
Department of Infectious Diseases, Cleveland Clinic Foundation, OH 44195, USA. mossads@ccf.org
D000547:Amantadine / Q000494:pharmacology; D000998:Antiviral Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000517:prevention & control*; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D053139:Oseltamivir / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D012299:Rimantadine / Q000494:pharmacology; D053243:Zanamivir / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D000998:Antiviral Agents; D012299:Rimantadine; D053139:Oseltamivir; D000547:Amantadine; D009439:Neuraminidase; D053243:Zanamivir